Tag Archive for: PARP inhibitor
PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair
/0 Comments/in Review/by MaxAMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1 Trial for ART-101, a Novel Radioligand Targeting PSMA in mCRPC June 21, 2025
- Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC June 20, 2025
- Phase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer June 20, 2025
- Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment June 20, 2025